866-997-4948(US-Canada Toll Free)

Human Papillomavirus Infections Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Metabolic Disorders

No. of Pages : 134 Pages


Global Markets Directs, \'Human Papillomavirus Infections Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Human Papillomavirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections. 

Human Papillomavirus Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Human Papillomavirus Infections.
  • A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Human Papillomavirus Infections pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Human Papillomavirus Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Human Papillomavirus Infections 9
Human Papillomavirus Infections Therapeutics under Development by Companies 11
Human Papillomavirus Infections Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Human Papillomavirus Infections Therapeutics Products under Development by Companies 20
Human Papillomavirus Infections Therapeutics Products under Investigation by Universities/Institutes 23
Companies Involved in Human Papillomavirus Infections Therapeutics Development 24
Photocure ASA 24
Helix BioPharma Corp. 25
Inovio Biomedical Corporation 26
Merck & Co., Inc. 27
MediGene AG 28
Isotechnika Pharma Inc. 29
Chong Kun Dang Pharmaceutical 30
Crucell N.V. 31
Bio-Bridge Science, Inc. 32
NanoViricides, Inc. 33
NexMed, Inc. 34
Starpharma Holdings Limited 35
Prima BioMed Limited 36
LG Life Sciences, Ltd 37
Bharat Biotech International Limited 38
Anaconda Pharma 39
Telormedix SA 40
ApoImmune, Inc. 41
Lumavita AG 42
BT PHARMA 43
Genetic Immunity, LLC 44
Sirnaomics, Inc. 45
Vaxart, Inc. 46
IRX Therapeutics, Inc. 47
Moberg Derma AB 48
Selecta Biosciences, Inc. 49
Inviragen, Inc. 50
Spider Biotech S.r.l. 51
EyeGene, Inc. 52
Vaccibody AS 53
Coridon Pty Ltd 54
Human Papillomavirus Infections Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Route of Administration 56
Assessment by Molecule Type 58
Drug Profiles 60
interferon alpha-2b - Drug Profile 60
HPV Vaccine - Drug Profile 61
TMX-202 - Drug Profile 62
ApoVax-104-HPV - Drug Profile 63
LMV-601 - Drug Profile 64
IRX-3 - Drug Profile 65
ProCervix - Drug Profile 66
V-503 - Drug Profile 67
bevacizumab - Drug Profile 69
human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant - Drug Profile 70
SPL-7013 - Drug Profile 72
celecoxib - Drug Profile 74
Albuterpenoid - Drug Profile 75
HPV Vaccine - Drug Profile 76
HupaDerm Vaccine - Drug Profile 77
Human Papillomavirus Vaccine - Drug Profile 78
HPV Vaccine - Drug Profile 79
RBT-201 - Drug Profile 80
hexaminolevulinate hydrochloride - Drug Profile 81
fluorouracil - Drug Profile 82
imiquimod - Drug Profile 83
HPV Vaccine - Drug Profile 84
AAVLP Program - Drug Profile 85
EG-HPV - Drug Profile 87
AP-611074 - Drug Profile 88
SynCon HPV Vaccine - Drug Profile 89
Human Papillomavirus Vaccine - Drug Profile 90
First Generation Bivalent HPV Vaccine - Drug Profile 91
HPV Vaccine - Drug Profile 92
CKD-12201 - Drug Profile 93
Universal human papillomavirus vaccine - Drug Profile 94
HerpeCide-I - Drug Profile 95
PL-202 - Drug Profile 96
SB-105 - Drug Profile 97
AV2-DM Antiviral Spray - Drug Profile 98
HPV Vaccine - Drug Profile 99
VB-1016 - Drug Profile 100
NICAM Program - Drug Profile 101
Therapeutic HPV Vaccine - Drug Profile 103
Second Generation Pentavalent HPV Vaccine - Drug Profile 104
Second Generation Trivalent HPV Vaccine - Drug Profile 105
STP-909 - Drug Profile 106
Human Papilloma Virus Vaccine - Drug Profile 107
Human Papilloma Virus Vaccine - Drug Profile 108
HSPG-Containing Infection Complex Antagonists - Drug Profile 109
Human Papillomavirus Infections Therapeutics Drug Profile Updates 110
Human Papillomavirus Infections Therapeutics Discontinued Products 119
Human Papillomavirus Infections Therapeutics - Dormant Products 120
Human Papillomavirus Infections Product Development Milestones 123
Featured News & Press Releases 123

Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 131
Disclaimer 131

List of Table


Number of Products Under Development for Human Papillomavirus Infections, H1 2013 12
Products under Development for Human Papillomavirus Infections Comparative Analysis, H1 2013 13
Number of Products under Development by Companies, H1 2013 15
Number of Products under Development by Companies, H1 2013 (Contd..1) 16
Number of Products under Development by Companies, H1 2013 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2013 18
Comparative Analysis by Late Stage Development, H1 2013 19
Comparative Analysis by Mid Clinical Stage Development, H1 2013 20
Comparative Analysis by Early Clinical Stage Development, H1 2013 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Development by Companies, H1 2013 (Contd..1) 24
Products under Development by Companies, H1 2013 (Contd..2) 25
Products under Investigation by Universities/Institutes, H1 2013 26
Photocure ASA, H1 2013 27
Helix BioPharma Corp., H1 2013 28
Inovio Biomedical Corporation, H1 2013 29
Merck & Co., Inc., H1 2013 30
MediGene AG, H1 2013 31
Isotechnika Pharma Inc., H1 2013 32
Chong Kun Dang Pharmaceutical, H1 2013 33
Crucell N.V., H1 2013 34
Bio-Bridge Science, Inc., H1 2013 35
NanoViricides, Inc., H1 2013 36
NexMed, Inc., H1 2013 37
Starpharma Holdings Limited, H1 2013 38
Prima BioMed Limited, H1 2013 39
LG Life Sciences, Ltd, H1 2013 40
Bharat Biotech International Limited, H1 2013 41
Anaconda Pharma, H1 2013 42
Telormedix SA, H1 2013 43
ApoImmune, Inc., H1 2013 44
Lumavita AG, H1 2013 45
BT PHARMA, H1 2013 46
Genetic Immunity, LLC, H1 2013 47
Sirnaomics, Inc., H1 2013 48
Vaxart, Inc., H1 2013 49
IRX Therapeutics, Inc., H1 2013 50
Moberg Derma AB, H1 2013 51
Selecta Biosciences, Inc., H1 2013 52
Inviragen, Inc., H1 2013 53
Spider Biotech S.r.l., H1 2013 54
EyeGene, Inc., H1 2013 55
Vaccibody AS, H1 2013 56
Coridon Pty Ltd, H1 2013 57
Assessment by Monotherapy Products, H1 2013 58
Assessment by Stage and Route of Administration, H1 2013 60
Assessment by Stage and Molecule Type, H1 2013 62
Human Papillomavirus Infections Therapeutics Drug Profile Updates 113
Human Papillomavirus Infections Therapeutics Discontinued Products 122
Human Papillomavirus Infections Therapeutics Dormant Products 123
Human Papillomavirus Infections Therapeutics Dormant Products (Contd..1) 124
Human Papillomavirus Infections Therapeutics Dormant Products (Contd..2) 125

List of Chart


Number of Products under Development for Human Papillomavirus Infections, H1 2013 12
Products under Development for Human Papillomavirus Infections Comparative Analysis, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 18
Late Stage Products, H1 2013 19
Mid Clinical Stage Products, H1 2013 20
Early Clinical Stage Products, H1 2013 21
Discovery and Pre-Clinical Stage Products, H1 2013 22
Assessment by Monotherapy Products, H1 2013 58
Assessment by Route of Administration, H1 2013 59
Assessment by Stage and Route of Administration, H1 2013 60
Assessment by Molecule Type, H1 2013 61
Assessment by Stage and Molecule Type, H1 2013 62

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *